Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research

Under stress from chemotherapy or radiation, some cancer cells dodge death by consuming a bit of themselves, allowing them to essentially sleep through treatment and later awaken as tougher, resistant disease.

4 Apr 2014

UCSF/Daiichi Sankyo establish drug-discovery collaboration focused on neurodegenerative diseases

Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and UC San Francisco (UCSF) announced today that they have established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases.

4 Apr 2014

CTMM, TI Pharma team up to create new public-private healthcare innovation

Leading Dutch technology institutes CTMM (Center for Translational Molecular Medicine) and TI Pharma have joined forces, in a merger that addresses the growing interdependence of medicines and medical technology.

3 Apr 2014

Adherent Health announces results of 2014 Patient Preference Study

Adherent Health, LLC, a mobile health engagement advisory focused on medication safe-use, adherence, and health outcomes attainment, announced today the results of its 2014 Patient Preference Study which surveyed the mobile app behaviors and medication support preferences of 2,216 prescription-taking patients aged 18-65+.

3 Apr 2014

Foundation Medicine, Clovis Oncology expand collaboration to develop novel companion diagnostic test

Foundation Medicine, Inc. and Clovis Oncology, Inc. today announced the expansion of their ongoing collaboration to incorporate a coordinated regulatory strategy for the development of a novel Premarket Approval (PMA) companion diagnostic test.

3 Apr 2014

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Crescendo Biologics Limited today announces it has raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals £19.5m. It was led by Imperial Innovations and included new investor Astellas Venture Management. Founding seed investor Sofinnova Partners also contributed significantly to the round.

3 Apr 2014

Auxogyn signs exclusive license agreement with Merck Serono for Eeva Test

Auxogyn, Inc., a company dedicated to advancing women's reproductive health, today announced an exclusive license agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada, for Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test.

3 Apr 2014

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.

3 Apr 2014

Actavis opens new regional headquarters in Singapore

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region.

3 Apr 2014

ABL enters into licensing agreement with CRP-Santé for COMET software

Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based company today announced that it has entered into an exclusive worldwide licensing agreement with CRP-Santé, a Luxembourg-based public research center active in the field of clinically oriented biomedical research, for its COMET (COntext-based Modeling for Expeditious Typing) software, a tool designed to rapidly analyze and optimally subtype large genetic data sets arising from epidemiological or antiretroviral resistance in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) fields.

2 Apr 2014

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

2 Apr 2014

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

BioAlliance Pharma SA, an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces an exclusive supply and license agreement for Sitavig® (Acyclovir Lauriad®) with Daewoong Pharmaceutical Co., Ltd. for commercialization rights in South Korea.

2 Apr 2014

Study shows important parallels between epidemic of HIV/AIDS and opioid addiction

There are important parallels between the early years of the HIV/AIDS epidemic and the current epidemic of opioid addiction - ones that could trigger a significant shift in opioid addiction prevention, diagnosis and treatment.

2 Apr 2014

FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.

2 Apr 2014

Evotec signs research collaboration and licensing deal with Debiopharm Group

Evotec AG announced today a research collaboration and licensing deal with Debiopharm Group™, Lausanne, Switzerland.

2 Apr 2014

Scientists discover how MRP-14 gene generates dangerous clots that could trigger heart attack

Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.

2 Apr 2014

Study demonstrates efficacy, tolerability of vemurafenib in aggressive form of metastatic melanoma

The Lancet Oncology has published results from the largest ever trial of a single melanoma treatment. The open label safety study was conducted to assess the tolerability of Zelboraf (vemurafenib), and featured 3,222 patients from across 44 countries.1 246 of these patients were from the UK.

2 Apr 2014

Actavis announces acquisition of Silom Medical for $100 million

Actavis plc, a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash.

1 Apr 2014

FORMA Therapeutics signs second strategic collaboration and option agreement with Celgene

FORMA Therapeutics, an innovative R&D organization in pursuit of ground-breaking medicines in oncology and other therapeutic areas, today announced a second strategic collaboration and option agreement with Celgene Corporation, a leader in addressing high unmet medical needs.

1 Apr 2014

EMD Serono collaborates with Pfizer and Broad Institute

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients.

1 Apr 2014

Oncology News and Research

Further Reading

Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research

UCSF/Daiichi Sankyo establish drug-discovery collaboration focused on neurodegenerative diseases

CTMM, TI Pharma team up to create new public-private healthcare innovation

Adherent Health announces results of 2014 Patient Preference Study

Foundation Medicine, Clovis Oncology expand collaboration to develop novel companion diagnostic test

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Auxogyn signs exclusive license agreement with Merck Serono for Eeva Test

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Actavis opens new regional headquarters in Singapore

ABL enters into licensing agreement with CRP-Santé for COMET software

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

Study shows important parallels between epidemic of HIV/AIDS and opioid addiction

FDA grants orphan drug designation to ERYTECH’s lead product for AML treatment

Evotec signs research collaboration and licensing deal with Debiopharm Group

Scientists discover how MRP-14 gene generates dangerous clots that could trigger heart attack

Study demonstrates efficacy, tolerability of vemurafenib in aggressive form of metastatic melanoma

Actavis announces acquisition of Silom Medical for $100 million

FORMA Therapeutics signs second strategic collaboration and option agreement with Celgene

EMD Serono collaborates with Pfizer and Broad Institute

A best-practice guide for laboratory services in oncology trials eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News